Register for our free email digests:
Armstrong Pharmaceuticals Inc.
Division of Amphastar Pharmaceuticals Inc.
http://www.armstrong-pharma.com
Latest From Armstrong Pharmaceuticals Inc.
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Primatene Mist NDA Expected By July After FDA OKs OTC Asthma Inhaler Trial
Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.
Primatene Mist CRL Underscores Challenges For OTC Asthma Treatments
Second FDA complete response letter for a reformulated Primatene Mist likely pushes back by another 18 months Amphastar's potential relaunch of the OTC product after satisfying the US agency's concerns about consumers correcting using the product without a doctor’s intervention.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Amphastar Pharmaceuticals Inc.
- Senior Management
- Contact Info
-
Armstrong Pharmaceuticals Inc.
Phone: (617) 323-7404
423 LaGrange St
West Roxbury, MA 02132
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice